STOCKWATCH
·
Biotechnology: Biological Products (No Diagnostic Substances)
Management ChangeMay 6, 2026, 04:03 PM

argenx Appoints Karen Massey as CEO; Tim Van Hauwermeiren Becomes Chair

AI Summary

argenx SE announced a leadership transition following its Annual General Meeting. Karen Massey, previously Chief Operating Officer, has been appointed Chief Executive Officer, succeeding co-founder Tim Van Hauwermeiren. Mr. Van Hauwermeiren will now serve as Chairperson of the Board of Directors. The AGM also approved the 2025 remuneration report, annual report, profit allocation, and authorized the issuance of up to 10% of the company's share capital.

Key Highlights

  • Karen Massey appointed Chief Executive Officer of argenx SE.
  • Tim Van Hauwermeiren, co-founder and former CEO, appointed Chairperson of the Board.
  • Shareholders approved Karen Massey's appointment as executive director for 4 years.
  • Shareholders approved Tim Van Hauwermeiren's appointment as non-executive director for 4 years.
  • AGM approved the 2025 remuneration report and annual report/accounts.
  • AGM approved allocation of 2025 profits to retained earnings.
  • Shareholders authorized issuing up to 10% of share capital for 18 months.
ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
ARGENX SE

Price Impact